Pub Date : 2021-01-01DOI: 10.35248/0975-0851.21.13.426
Rami Vivek
Gastro retentive medication conveyance frameworks have been investigated for controlling the arrival of the medications by oral organization These frameworks are in touch with the gastric substance for longer time and subsequently, "Food" is required to meddle with the pace of assimilation from these frameworks. This article centers around different food sources related elements liable for influencing assimilation from the GRDDS kind of novel framework.
{"title":"Effect of Food through Drug Delivery System","authors":"Rami Vivek","doi":"10.35248/0975-0851.21.13.426","DOIUrl":"https://doi.org/10.35248/0975-0851.21.13.426","url":null,"abstract":"Gastro retentive medication conveyance frameworks have been investigated for controlling the arrival of the medications by oral organization These frameworks are in touch with the gastric substance for longer time and subsequently, \"Food\" is required to meddle with the pace of assimilation from these frameworks. This article centers around different food sources related elements liable for influencing assimilation from the GRDDS kind of novel framework.","PeriodicalId":15184,"journal":{"name":"Journal of Bioequivalence & Bioavailability","volume":"44 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77622137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.35248/0975-0851.21.S2.001
Santif Gen
Allopurinol is a compelling inhibitor of the catalyst xanthine oxidase, use for diminishing the blood centralizations of urate and, in this manner, to diminish the amount of rehashed attacks of gout. Allopurinol is used to oxipurinol, and hypouricaemic adequacy of allopurinol is expected in enormous part to this metabolite.
{"title":"Bioavailability and bioequivalence of allopurinol in two tablet formulations","authors":"Santif Gen","doi":"10.35248/0975-0851.21.S2.001","DOIUrl":"https://doi.org/10.35248/0975-0851.21.S2.001","url":null,"abstract":"Allopurinol is a compelling inhibitor of the catalyst xanthine oxidase, use for diminishing the blood centralizations of urate and, in this manner, to diminish the amount of rehashed attacks of gout. Allopurinol is used to oxipurinol, and hypouricaemic adequacy of allopurinol is expected in enormous part to this metabolite.","PeriodicalId":15184,"journal":{"name":"Journal of Bioequivalence & Bioavailability","volume":"82 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83753421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.35248/0975-0851.21.S1.E002
D. Sebastian
In pharmacology, bioavailability (BA or F) is a subcategory of retention and is the part (%) of a controlled medication that arrives at the foundational flow.
在药理学中，生物利用度(BA或F)是保留率的一个子类，是受控药物到达基础流的部分(%)。
{"title":"Deviation Range to Address Genuine Bioavailability","authors":"D. Sebastian","doi":"10.35248/0975-0851.21.S1.E002","DOIUrl":"https://doi.org/10.35248/0975-0851.21.S1.E002","url":null,"abstract":"In pharmacology, bioavailability (BA or F) is a subcategory of retention and is the part (%) of a controlled medication that arrives at the foundational flow.","PeriodicalId":15184,"journal":{"name":"Journal of Bioequivalence & Bioavailability","volume":"56 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76899991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.35248/0975-0851.21.S1.E004
C. Dobrea
Pharmacokinetics (from Ancient Greek pharmakon "drug" and kinetikos "moving, placing moving"; see synthetic energy), now and then curtailed as PK, is a part of pharmacology devoted to decide the destiny of substances directed to a living creature.
{"title":"Pharmacokinetics and Condensed New Drug Application","authors":"C. Dobrea","doi":"10.35248/0975-0851.21.S1.E004","DOIUrl":"https://doi.org/10.35248/0975-0851.21.S1.E004","url":null,"abstract":"Pharmacokinetics (from Ancient Greek pharmakon \"drug\" and kinetikos \"moving, placing moving\"; see synthetic energy), now and then curtailed as PK, is a part of pharmacology devoted to decide the destiny of substances directed to a living creature.","PeriodicalId":15184,"journal":{"name":"Journal of Bioequivalence & Bioavailability","volume":"88 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83828746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.35248/0975-0851.21.S3.003
R. Thomas
Maturing is frequently joined by a decrease in psychological and engine capacities and in emotional wellness. Albeit thought about piece of maturing, these conditions may have nutrient B12 inadequacy as a hidden instrument. Exploration on the impact of nutrient B12 on cerebrum wellbeing has dwindled down as numerous investigations revealed negative relationship among vB12D and mind wellbeing. Nonetheless, numerous patients show wide or minor side effects that leave vB12D undocumented.
{"title":"Vitamin B12 for Cognitive Functions in Elderly","authors":"R. Thomas","doi":"10.35248/0975-0851.21.S3.003","DOIUrl":"https://doi.org/10.35248/0975-0851.21.S3.003","url":null,"abstract":"Maturing is frequently joined by a decrease in psychological and engine capacities and in emotional wellness. Albeit thought about piece of maturing, these conditions may have nutrient B12 inadequacy as a hidden instrument. Exploration on the impact of nutrient B12 on cerebrum wellbeing has dwindled down as numerous investigations revealed negative relationship among vB12D and mind wellbeing. Nonetheless, numerous patients show wide or minor side effects that leave vB12D undocumented.","PeriodicalId":15184,"journal":{"name":"Journal of Bioequivalence & Bioavailability","volume":"83 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82657677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.35248/0975-0851.21.13.427
Erdal Dani
A few examinations with formed unsaturated fats have been completed by our gathering. They have been proposed by the creators of this for over 30 years. This specific exploration with formed unsaturated fats was begun and grown over six years prior. The examination's point has been to explain their parts of wellbeing, bioavailability, and usefulness. Formed unsaturated fats essentially begin from the linoleic (CLA) and the linolenic (CLNA) unsaturated fats, through substance, enzymatic and metabolic cycles. With respect to their primary structures, they can be described when they are contrasted with the unsaturated fats that led to them, where the change from unconjugated twofold securities to formation happens.
{"title":"Effect of Fatty Acids on Bioavailability","authors":"Erdal Dani","doi":"10.35248/0975-0851.21.13.427","DOIUrl":"https://doi.org/10.35248/0975-0851.21.13.427","url":null,"abstract":"A few examinations with formed unsaturated fats have been completed by our gathering. They have been proposed by the creators of this for over 30 years. This specific exploration with formed unsaturated fats was begun and grown over six years prior. The examination's point has been to explain their parts of wellbeing, bioavailability, and usefulness. Formed unsaturated fats essentially begin from the linoleic (CLA) and the linolenic (CLNA) unsaturated fats, through substance, enzymatic and metabolic cycles. With respect to their primary structures, they can be described when they are contrasted with the unsaturated fats that led to them, where the change from unconjugated twofold securities to formation happens.","PeriodicalId":15184,"journal":{"name":"Journal of Bioequivalence & Bioavailability","volume":"171 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73401481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.35248/0975-0851.21.S2.E002
L. Roche
Bioavailability is alluded to as the degree and rate to which the dynamic medication fixing or dynamic moiety from the medication item is ingested and opens up at the site of medication activity. The general bioavailability as far as the rate and degree of medication ingestion is viewed as prescient of clinical results. In 1984, the United States Food and Drug Administration (FDA) was approved to endorse conventional medication items under the Drug Price Competition and Patent Term Restoration Act dependent on proof of normal bioequivalence in drug assimilation through the direct of bioavailability and bioequivalence considers.
{"title":"Short Note on Drug Development","authors":"L. Roche","doi":"10.35248/0975-0851.21.S2.E002","DOIUrl":"https://doi.org/10.35248/0975-0851.21.S2.E002","url":null,"abstract":"Bioavailability is alluded to as the degree and rate to which the dynamic medication fixing or dynamic moiety from the medication item is ingested and opens up at the site of medication activity. The general bioavailability as far as the rate and degree of medication ingestion is viewed as prescient of clinical results. In 1984, the United States Food and Drug Administration (FDA) was approved to endorse conventional medication items under the Drug Price Competition and Patent Term Restoration Act dependent on proof of normal bioequivalence in drug assimilation through the direct of bioavailability and bioequivalence considers.","PeriodicalId":15184,"journal":{"name":"Journal of Bioequivalence & Bioavailability","volume":"32 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89153896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.35248/0975-0851.20.12.410
F. Sorgel
{"title":"Bioequivalence Studies for Generic Drug Development","authors":"F. Sorgel","doi":"10.35248/0975-0851.20.12.410","DOIUrl":"https://doi.org/10.35248/0975-0851.20.12.410","url":null,"abstract":"","PeriodicalId":15184,"journal":{"name":"Journal of Bioequivalence & Bioavailability","volume":"3 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74240756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.35248/0975-0851.20.12.391
A. Arumugam, A. Mani, J. Chirinos
Background: Idelalisib, a PI3K small molecule inhibitor, specifically blocks the phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit delta isoform (PI3Kδ). This is a potent drug which is specifically targeted for relapsed chronic lymphocytic leukemia (CLL). Methods and Findings: A full replicate bioequivalence study of two Idelalisib 150 mg tablets was conducted in 56 healthy adult human subjects under fasting conditions with a washout period of 10 days in between doses. Blood samples were collected up to 72 hours post-dose for measurement of pharmacokinetic parameters in all periods to quantify Idelalisib in human plasma using a validated LC-MS/MS method. Bioequivalence between both the products was established by calculating 90% confidence intervals (90% CI) for the ratio of Cmax and AUC0-t values for the test and reference products. The 90% confidence intervals found for the relation of Test/Reference were Cmax 92.23% - 106.06% and AUC0-t 96.62% - 105.27%. Conclusion: According to FDA's guidelines for Bioequivalence research and based on the ANOVA results obtained, it can be concluded that Idelalisib 150 mg tablets of Abbott Laboratories de Colombia is bioequivalent to Zydelig (Idelalisib) 150 mg tablets of Gilead Sciences Ltd under fasting conditions.
{"title":"A Full Replicate in vivo Bioequivalence Study of Two Idelalisib 150 mg Tablets in Fasted Healthy Adult Human Subjects","authors":"A. Arumugam, A. Mani, J. Chirinos","doi":"10.35248/0975-0851.20.12.391","DOIUrl":"https://doi.org/10.35248/0975-0851.20.12.391","url":null,"abstract":"Background: Idelalisib, a PI3K small molecule inhibitor, specifically blocks the phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit delta isoform (PI3Kδ). This is a potent drug which is specifically targeted for relapsed chronic lymphocytic leukemia (CLL). Methods and Findings: A full replicate bioequivalence study of two Idelalisib 150 mg tablets was conducted in 56 healthy adult human subjects under fasting conditions with a washout period of 10 days in between doses. Blood samples were collected up to 72 hours post-dose for measurement of pharmacokinetic parameters in all periods to quantify Idelalisib in human plasma using a validated LC-MS/MS method. Bioequivalence between both the products was established by calculating 90% confidence intervals (90% CI) for the ratio of Cmax and AUC0-t values for the test and reference products. The 90% confidence intervals found for the relation of Test/Reference were Cmax 92.23% - 106.06% and AUC0-t 96.62% - 105.27%. Conclusion: According to FDA's guidelines for Bioequivalence research and based on the ANOVA results obtained, it can be concluded that Idelalisib 150 mg tablets of Abbott Laboratories de Colombia is bioequivalent to Zydelig (Idelalisib) 150 mg tablets of Gilead Sciences Ltd under fasting conditions.","PeriodicalId":15184,"journal":{"name":"Journal of Bioequivalence & Bioavailability","volume":"34 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87955944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：